CellaVision AB (publ) (CEVI.ST)
- Previous Close
194.00 - Open
190.80 - Bid 198.20 x --
- Ask 198.60 x --
- Day's Range
190.80 - 199.40 - 52 Week Range
147.80 - 302.00 - Volume
8,887 - Avg. Volume
26,676 - Market Cap (intraday)
4.727B - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
31.07 - EPS (TTM)
6.38 - Earnings Date Jul 17, 2025
- Forward Dividend & Yield 2.50 (1.29%)
- Ex-Dividend Date May 7, 2025
- 1y Target Est
230.00
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas is an app with morphology experts for series mini lectures on extensive cell image library introduction to cell morphology; CellaVision Remote Review Software removes restrictive geographical constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
www.cellavision.comRecent News: CEVI.ST
View MorePerformance Overview: CEVI.ST
Trailing total returns as of 6/9/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CEVI.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CEVI.ST
View MoreValuation Measures
Market Cap
4.63B
Enterprise Value
4.47B
Trailing P/E
30.41
Forward P/E
26.18
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.19
Price/Book (mrq)
5.52
Enterprise Value/Revenue
5.97
Enterprise Value/EBITDA
22.80
Financial Highlights
Profitability and Income Statement
Profit Margin
20.34%
Return on Assets (ttm)
12.14%
Return on Equity (ttm)
19.05%
Revenue (ttm)
747.94M
Net Income Avi to Common (ttm)
152.12M
Diluted EPS (ttm)
6.38
Balance Sheet and Cash Flow
Total Cash (mrq)
182.32M
Total Debt/Equity (mrq)
2.74%
Levered Free Cash Flow (ttm)
60.52M